Abstract
Various prospective trials which employed genetic allocation of post-remission treatment have been performed to assess the role of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of AML in CR1. However, it has been difficult to clearly demonstrate the clinical benefit of allo-HCT in patients with AML in CR1. A decision analysis with the Markov process is a flexible and convenient analytical method that tracks the clinical events that occur after a certain decision with different probabilities over time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
